Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Invesco Ltd.

Key Points

• Invesco Ltd. has sold 246,735 shares of Ironwood Pharmaceuticals, reducing its stake by 47.3%, leaving it with approximately 275,253 shares valued at $405,000.
• Ironwood Pharmaceuticals recently reported $85.24 million in revenue for the quarter, exceeding analysts' expectations, and earnings of $0.14 per share, beating the consensus estimate.
• Analysts have upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating, with a consensus average price target of $4.94 for the stock.

Invesco Ltd. cut its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 47.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 275,253 shares of the biotechnology company's stock after selling 246,735 shares during the quarter. Invesco Ltd. owned approximately 0.17% of Ironwood Pharmaceuticals worth $405,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter worth about $36,000. Hsbc Holdings PLC raised its position in shares of Ironwood Pharmaceuticals by 88.9% during the 4th quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company's stock worth $91,000 after acquiring an additional 9,828 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Ironwood Pharmaceuticals by 4.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 218,422 shares of the biotechnology company's stock worth $968,000 after purchasing an additional 10,149 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Ironwood Pharmaceuticals by 28.9% in the fourth quarter. ProShare Advisors LLC now owns 50,204 shares of the biotechnology company's stock valued at $222,000 after purchasing an additional 11,267 shares in the last quarter. Finally, Envestnet Asset Management Inc. purchased a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $50,000.

Analyst Ratings Changes

Several brokerages recently commented on IRWD. Zacks Research lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 5th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Ironwood Pharmaceuticals currently has an average rating of "Hold" and an average price target of $4.94.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock traded up $0.09 during mid-day trading on Thursday, reaching $1.24. 1,208,423 shares of the company were exchanged, compared to its average volume of 1,246,201. The firm's 50-day simple moving average is $0.97 and its two-hundred day simple moving average is $0.98. Ironwood Pharmaceuticals, Inc. has a twelve month low of $0.53 and a twelve month high of $5.13. The firm has a market cap of $201.41 million, a PE ratio of -24.80 and a beta of 0.33.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The business had revenue of $85.24 million during the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.